Development and Validation of an Immunoassay for Quantification of Topoisomerase I in Solid Tumor Tissues
作者： Thomas D. Pfister , Melinda Hollingshead , Robert J. Kinders , Yiping Zhang , Yvonne A. Evrard
DOI: 10.1371/JOURNAL.PONE.0050494
关键词:
摘要: Background Topoisomerase I (Top1) is a proven target for cancer therapeutics. Recent data from the Fluorouracil, Oxaliplatin, CPT-11: Use and Sequencing (FOCUS) trial demonstrated that nuclear staining of Top1 correlates with chemotherapeutic efficacy. Such correlation may help identify patients likely to respond inhibitors illuminate their mechanism action. Cellular response complex, but engagement necessary first step in this process. This paper reports development validation quantitative immunoassay tumors.
elsevier.com
paperity.org
core.ac.uk 参考文章(48)
Yaw-Huei Hsiang, Leroy F. Liu, Identification of Mammalian DNA Topoisomerase I as an Intracellular Target of the Anticancer Drug Camptothecin Cancer Research. ,vol. 48, pp. 1722- 1726 ,(1988)
Miriam Koopman, Ninja F Antonini, Joep Douma, Jaap Wals, Aafke H Honkoop, Frans LG Erdkamp, Robert S de Jong, Cees J Rodenburg, Gerard Vreugdenhil, Olaf JL Loosveld, Aart van Bochove, Harm AM Sinnige, Geert-Jan M Creemers, Margot ET Tesselaar, Peter H Th J Slee, Marjon JBP Werter, Linda Mol, Otilia Dalesio, Cornelis JA Punt, Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. The Lancet. ,vol. 370, pp. 135- 142 ,(2007) , 10.1016/S0140-6736(07)61086-1
Shyamal D. Desai, Hui Zhang, Alexandra Rodriguez-Bauman, Jin-Ming Yang, Xiaohua Wu, Murugesan K. Gounder, Eric H. Rubin, Leroy F. Liu, Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Molecular and Cellular Biology. ,vol. 23, pp. 2341- 2350 ,(2003) , 10.1128/MCB.23.7.2341-2350.2003
Robert J Kinders, Melinda Hollingshead, Scott Lawrence, Jiuping Ji, Brian Tabb, William M Bonner, Yves Pommier, Larry Rubinstein, Yvonne A Evrard, Ralph E Parchment, Joseph Tomaszewski, James H Doroshow, None, Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity Clinical Cancer Research. ,vol. 16, pp. 5447- 5457 ,(2010) , 10.1158/1078-0432.CCR-09-3076
Michel Pluot, Jérome Devy, Alyona Sukhanova, Igor Nabiev, Richard Wargnier, Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines Anticancer Research. ,vol. 24, pp. 1745- 1751 ,(2004)
Yung-Chi Cheng, Susan Grill, Qin Fu, Seung-Whan Kim, Hong-Xin Chen, DEGRADATION OF TOPOISOMERASE I INDUCED BY TOPOISOMERASE I INHIBITORS IS DEPENDENT ON INHIBITOR STRUCTURE BUT INDEPENDENT OF CELL DEATH Molecular Pharmacology. ,vol. 55, pp. 677- 683 ,(1999)
D. R. Beidler, Yung-Chi Cheng, Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Molecular Pharmacology. ,vol. 47, pp. 907- 914 ,(1995)
DNA Topoisomerases and Cancer Springer New York. ,(2012) , 10.1007/978-1-4614-0323-4
Yan Makeyev, Franco Muggia, Arun Rajan, Giuseppe Giaccone, Takahisa Furuta, Philippe Rougier, Topoisomerase I Inhibitors: Current Use and Prospects Cancer Drug Discovery and Development. pp. 245- 277 ,(2012) , 10.1007/978-1-4614-0323-4_12
Jacqueline Plowman, Donald J. Dykes, Melinda Hollingshead, Linda Simpson-Herren, Michael C. Alley, Human Tumor Xenograft Models in NCI Drug Development Anticancer Drug Development Guide. pp. 101- 125 ,(1997) , 10.1007/978-1-4615-8152-9_6